Juanita Lopez

10.1k total citations · 4 hit papers
144 papers, 4.9k citations indexed

About

Juanita Lopez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Juanita Lopez has authored 144 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Juanita Lopez's work include Cancer Immunotherapy and Biomarkers (42 papers), Cancer Genomics and Diagnostics (22 papers) and Glioma Diagnosis and Treatment (19 papers). Juanita Lopez is often cited by papers focused on Cancer Immunotherapy and Biomarkers (42 papers), Cancer Genomics and Diagnostics (22 papers) and Glioma Diagnosis and Treatment (19 papers). Juanita Lopez collaborates with scholars based in United Kingdom, United States and Spain. Juanita Lopez's co-authors include Udai Banerji, Pascal Meier, Jessica Brown, Sanatan Saraf, Patrick A. Ott, Emilie M.J. van Brummelen, Raghav Sundar, Tencho Tenev, Jean‐Charles Soria and Meike Broemer and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Juanita Lopez

136 papers receiving 4.9k citations

Hit Papers

T-Cell–Inflamed Gene-Expression Profile, Progr... 2011 2026 2016 2021 2018 2011 2017 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
    2018 656 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  2. The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs
    2011 653 citations Juanita Lopez et al. profile →
  3. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    2017 377 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  4. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    2017 325 citations Juanita Lopez, Sanatan Saraf et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juanita Lopez United Kingdom 28 2.6k 1.9k 1.3k 1.2k 821 144 4.9k
Drew Rasco United States 33 2.4k 0.9× 1.7k 0.9× 980 0.8× 870 0.7× 516 0.6× 192 4.1k
Matthew H. Taylor United States 36 3.5k 1.3× 1.4k 0.7× 1.6k 1.2× 1.1k 0.9× 687 0.8× 173 6.4k
Takeshi Kuwata Japan 43 2.9k 1.1× 1.9k 1.0× 1.8k 1.4× 1.4k 1.1× 901 1.1× 198 5.9k
Bartosz Chmielowski United States 41 4.4k 1.7× 2.6k 1.4× 1.8k 1.4× 1.8k 1.5× 506 0.6× 180 7.0k
Isabelle Treilleux France 47 3.6k 1.4× 3.1k 1.7× 810 0.6× 2.3k 1.9× 1.7k 2.0× 219 7.9k
Ignacio Garrido‐Laguna United States 32 3.1k 1.2× 1.8k 1.0× 1.1k 0.9× 493 0.4× 1.5k 1.8× 160 4.9k
Paul Haluska United States 38 2.0k 0.8× 2.5k 1.3× 618 0.5× 497 0.4× 1.1k 1.4× 114 4.9k
Janice M. Mehnert United States 26 2.5k 1.0× 886 0.5× 776 0.6× 969 0.8× 648 0.8× 63 3.7k
Junzo Hamanishi Japan 33 4.4k 1.7× 1.7k 0.9× 965 0.8× 3.6k 2.9× 873 1.1× 142 7.4k
Helen K. Angell United Kingdom 22 4.0k 1.6× 2.1k 1.1× 1.9k 1.5× 2.7k 2.3× 1.4k 1.7× 40 6.5k

Countries citing papers authored by Juanita Lopez

Since Specialization
Citations

This map shows the geographic impact of Juanita Lopez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juanita Lopez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juanita Lopez more than expected).

Fields of papers citing papers by Juanita Lopez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juanita Lopez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juanita Lopez. The network helps show where Juanita Lopez may publish in the future.

Co-authorship network of co-authors of Juanita Lopez

This figure shows the co-authorship network connecting the top 25 collaborators of Juanita Lopez. A scholar is included among the top collaborators of Juanita Lopez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juanita Lopez. Juanita Lopez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zachariou, Athanasios, Sudhir Venkatesan, Xiaolin Hu, et al.. (2025). 85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20(3). S62–S63.
3.
Kim, Hye Ryun, Omar Saavedra, Andrés Cervantes, et al.. (2024). Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 2522–2522. 9 indexed citations
4.
Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521. 3 indexed citations
5.
6.
Friedman, Claire F., Juanita Lopez, Mark R. Middleton, et al.. (2024). 750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC). Annals of Oncology. 35. S569–S570. 1 indexed citations
7.
Lopez, Juanita, Julia Lai‐Kwon, R. Molife, et al.. (2023). A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. British Journal of Cancer. 129(5). 811–818. 10 indexed citations
8.
Lopez, Juanita, Simon Haefliger, Ruth Plummer, et al.. (2023). Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.. Journal of Clinical Oncology. 41(16_suppl). 2044–2044. 1 indexed citations
9.
Pal, Abhijit, Andrea Biondo, Alex Pui‐Wai Lee, et al.. (2021). A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. SHILAP Revista de lepidopterología. 4(4). 189–195. 5 indexed citations
10.
Yap, Timothy A., Matthew Krebs, Sophie Postel‐Vinay, et al.. (2021). Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 27(19). 5213–5224. 71 indexed citations
11.
Davar, Diwakar, Randy F. Sweis, George Blumenschein, et al.. (2021). 91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein. Annals of Oncology. 32. S1411–S1413. 5 indexed citations
12.
Terbuch, Angelika, Mariana Scaranti, Andra Curcean, et al.. (2020). Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical Cancer Research. 26(18). 4805–4813. 13 indexed citations
13.
14.
Yap, Timothy A., Jane N. Winter, Lisa Giulino‐Roth, et al.. (2019). Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research. 25(24). 7331–7339. 128 indexed citations
15.
Ramalingam, Sundar, Juanita Lopez, Morten Mau‐Sørensen, et al.. (2019). OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC. Journal of Thoracic Oncology. 14(10). S209–S209. 12 indexed citations
16.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2018). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Obstetrical & Gynecological Survey. 73(1). 26–27. 25 indexed citations
17.
Ott, Patrick A., Yung‐Jue Bang, Sarina A. Piha‐Paul, et al.. (2018). T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology. 37(4). 318–327. 656 indexed citations breakdown →
18.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(22). 2535–2541. 377 indexed citations breakdown →
19.
Chalmers, Anthony J., Garth Cruickshank, Laurence Dunn, et al.. (2017). ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM). Neuro-Oncology. 19(suppl_6). vi4–vi4. 14 indexed citations
20.
Ott, Patrick A., Y-J. Bang, A.R. Abdul Razak, et al.. (2017). Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028). Annals of Oncology. 28. v22–v22. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Drew Rasco Breakdown of academic impact, for papers by Matthew H. Taylor Breakdown of academic impact, for papers by Takeshi Kuwata Breakdown of academic impact, for papers by Bartosz Chmielowski Breakdown of academic impact, for papers by Isabelle Treilleux Breakdown of academic impact, for papers by Ignacio Garrido‐Laguna Breakdown of academic impact, for papers by Paul Haluska Breakdown of academic impact, for papers by Janice M. Mehnert Breakdown of academic impact, for papers by Junzo Hamanishi Breakdown of academic impact, for papers by Helen K. Angell
Rankless by CCL
2026